Evidence map›Paper›PMID 41357138›Full record

ArticleAnimal cells and systems2026

RepID promotes metastatic potential in osteosarcoma through regulation of the PRC1-GATA6 axis.

Dong-Hyun Jung, Jong-Uk Park, Jae-Hyun Jo, Dong-Kyu Kim, Yeong-Mu Kim, Min-Ju Kang, Suk-Hoon Hong, Hyo Je Cho, Jihoon Nah, Jun-Young Park and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Animal cells and systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dong-Hyun JungDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Jong-Uk ParkDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Jae-Hyun JoDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Dong-Kyu KimDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Yeong-Mu KimDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Min-Ju KangDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Suk-Hoon HongBachelor of Science in Molecular Biotechnology, Ghent University Global Campus, Incheon, South Korea.
Hyo Je ChoDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Jihoon NahDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Jun-Young ParkDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Jung-Hyun ChoiDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.
Sangjune KimDepartment of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, South Korea.
Sang-Min JangDepartment of Biochemistry, Chungbuk National University, Cheongju, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is the most common primary malignant bone tumor and is characterized by a high propensity for metastasis, most frequently to the lungs and lymph nodes. Despite extensive research, the key modulators and their functional roles driving osteosarcoma metastasis remain poorly defined. Here, we identify RepID (Replication initiation determinant protein), a substrate receptor which is crucial for the chromatin recruitment of the Cullin-RING ubiquitin E3 ligase 4 (CRL4) complex, as a upstream regulator of epithelial-mesenchymal transition (EMT)-associated gene expression that promotes osteosarcoma metastasis.

Indexed as

cell migrationEMTGATA6PRC1RepID

Identifiers

PMID41357138
PMCPMC12679852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.